Categories
Change Password!
Reset Password!
Hypertension and dyslipidemia commonly occur together, dramatically escalating the likelihood of cardiovascular (CV) mortality.
In adults with hypertension and dyslipidemia, telmisartan + amlodipine provides superior blood pressure reduction, while telmisartan + rosuvastatin provides greater LDL-C lowering, with comparable safety.
Hypertension and dyslipidemia commonly occur together, dramatically escalating the likelihood of cardiovascular (CV) mortality. Patients with both high blood pressure and elevated low-density lipoprotein cholesterol (LDL-C) often require dual-target therapy to successfully minimize overall CV risk.
Telmisartan, an extensively prescribed angiotensin II receptor blocker (ARB), is frequently combined with either:
This updated meta-analysis explored the comparative effectiveness, lipid-lowering impact, antihypertensive outcomes, and safety profile of these two commonly prescribed fixed-dose combinations in adults with hypertension and dyslipidemia.
A comprehensive search of randomized controlled trials (RCTs) was conducted using Cochrane Central, MEDLINE/PubMed, ClinicalTrials.gov, and ScienceDirect. Eligible studies encompassed adults (≥18 years) diagnosed with:
A random-effects meta-analysis model was implemented using RevMan 5.4.1. Risk of bias was checked via the Cochrane risk of bias tool. Statistical heterogeneity was measured utilizing the I² statistic.
In total, 3 RCTs with a total of 320 volunteers were analyzed. At 4 weeks, telmisartan + amlodipine led to a higher reduction in sitting systolic blood pressure (sSBP) as opposed to telmisartan + rosuvastatin. At 8 weeks, sitting diastolic blood pressure (sDBP) reductions were also more pronounced in the telmisartan + amlodipine group. In contrast, telmisartan + rosuvastatin produced greater LDL-C lowering, illustrating remarkable reductions at both 4 weeks and 8 weeks (Table 1).
The incidence of treatment-emergent adverse events was similar between groups (relative risk = 1.23).
For adults with hypertension and dyslipidemia, treatment should be individualized based on therapeutic goals:
Both combinations are well-tolerated and safe, supporting a personalized, risk-based approach to CV management.
Clinical Cardiology
Dual-Targeted Therapy in Cardiometabolic Risk: A Meta-Analysis of Telmisartan-Based Combinations for Hypertension and Dyslipidemia
Rabia Asim et al.
Comments (0)